The University of Chicago Header Logo

Connection

Adil Javed to Male

This is a "connection" page, showing publications Adil Javed has written about Male.
Connection Strength

0.223
  1. Validation of retroactively derived T1 relaxation values from 3D T1-weighted images with clinical and MRI measures of disability in multiple sclerosis. PLoS One. 2025; 20(5):e0323898.
    View in: PubMed
    Score: 0.046
  2. T1 mapping from routine 3D T1-weighted inversion recovery sequences in clinical practice: comparison against reference inversion recovery fast field echo T1 scans and feasibility in multiple sclerosis. Neuroradiology. 2024 Oct; 66(10):1709-1719.
    View in: PubMed
    Score: 0.043
  3. Reduction in ocrelizumab-induced infusion reactions by a modified premedication protocol. Mult Scler Relat Disord. 2019 Jan; 27:397-399.
    View in: PubMed
    Score: 0.029
  4. Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J Neurol Sci. 2012 Feb 15; 313(1-2):48-53.
    View in: PubMed
    Score: 0.018
  5. Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis. Mult Scler. 2008 Jul; 14(6):809-14.
    View in: PubMed
    Score: 0.014
  6. COVID-19 in multiple sclerosis patients and risk factors for severe infection. J Neurol Sci. 2020 Nov 15; 418:117147.
    View in: PubMed
    Score: 0.008
  7. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis. J Neuroinflammation. 2020 Jun 15; 17(1):189.
    View in: PubMed
    Score: 0.008
  8. D-Fenfluramine induces serotonin-mediated Fos expression in corticotropin-releasing factor and oxytocin neurons of the hypothalamus, and serotonin-independent Fos expression in enkephalin and neurotensin neurons of the amygdala. Neuroscience. 1999 Mar; 90(3):851-8.
    View in: PubMed
    Score: 0.007
  9. Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. PLoS One. 2018; 13(12):e0209326.
    View in: PubMed
    Score: 0.007
  10. The 5-HT1A and 5-HT2A/2C receptor antagonists WAY-100635 and ritanserin do not attenuate D-fenfluramine-induced fos expression in the brain. Brain Res. 1998 Apr 27; 791(1-2):67-74.
    View in: PubMed
    Score: 0.007
  11. A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab. Mult Scler. 2019 05; 25(6):811-818.
    View in: PubMed
    Score: 0.007
  12. Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. PLoS One. 2018; 13(1):e0190425.
    View in: PubMed
    Score: 0.007
  13. High resolution retinal scanning reveals regional structural differences between MS and NMOSD optic neuritis regardless of antibody status. J Neurol Sci. 2018 Jan 15; 384:61-66.
    View in: PubMed
    Score: 0.007
  14. p-Chlorophenylalanine and fluoxetine inhibit D-fenfluramine-induced Fos expression in the paraventricular nucleus, cingulate cortex and frontal cortex but not in other forebrain and brainstem regions. Brain Res. 1997 Nov 07; 774(1-2):94-105.
    View in: PubMed
    Score: 0.007
  15. Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study. PLoS One. 2017; 12(4):e0173299.
    View in: PubMed
    Score: 0.007
  16. 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J Neurosci. 2001 May 15; 21(10):3572-9.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.